|
Study Designed to Debunk Risks Raises Questions About Avandia Medicine
A study that was to put to rest the fear that Avandia medicine for Type 2 diabetes is linked with serious risks to users hearts, has instead reinforced the fear, according to an article in the New York Times (Diabetes Drug Still Has Heart Risks, Doctors Warn, June 6, 2007).
The Times article cites recent data posted online in the New England Journal of Medicine, which only intensified the controversy.
"In short, there is continued uncertainty about the cardiovascular safety of rosiglitazone," the Journal editors wrote, referring to the generic name of Avandia.
Additionally, according to the article, Dr. Rosemary Johann-Liang, a supervisor in the drug safety office at the Food & Drug Administration was called to the carpet for approving a warning on Avandia.
Reportedly, she was ordered to retract her warning and subsequently lost her power at the office to supervise reviews of the safety of Avandia.
If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.
see also:
FDA Warning, 5.22.07
FDA Alert on the Anti-Diabetes Drug Avandia: Risk of Heart AttackRisks to taking the drug Avandia include heart attack and chest pain
6.6.07 Study
Study Designed to Debunk Risks Raises Questions About Avandia MedicineAvandia Medicine Still Has Serious Heart Risks, Doctors Warn
FDA Warning, 6.6.07
FDA Issues Strictest Warning on Prescription Diabetes Drug AvandiaFDA Calls for Toughest Warning to be Placed on Avandia Prescription
